Structure and transcription of the nopaline synthase gene region of T-DNA

Michael Bevan*, Wayne M. Barnes1§ and Mary-Dell Chilton

Department of Biology, Washington University, and ¹Department of Biological Chemistry, Washington University School of Medicine, Saint Louis, MO 63110, USA

Received 12 October 1982; Revised and Accepted 10 December 1982

ABSTRACT

We present the DNA sequence and plant-tumor transcription pattern of some 2400 base pairs from the right border region of pTi T37 DNA from the virulent Agrobacterium tumefaciens strain T37. This region includes the entire transcription unit encompassing the nopaline synthase gene, together with parts of other transcription units. The strategy used to determine the sequence also produced two opposing series of defined, asymmetric deletions across the target DNA region, some of which may serve future purposes in the exploitation of this sequence, which is known to be expressed in a wide variety of host plant tissues.

INTRODUCTION

Crown gall tumors on dicotyledonous plants are incited by strains of Agrobacterium tumefaciens that harbor tumor-inducing, or Ti, plasmids. 1,2 A small segment of the plasmid, called T-DNA, is transferred to, and stably maintained in, the tumorous plant cells. T-DNA is covalently linked to plant nuclear DNA and encodes polyadenylated transcripts 10-12 some of which have been shown to encode proteins. 13

Axenic cultures of crown gall tumors are characterized by autonomous growth in the absence of the plant growth regulators auxin and cytokinin. 14 They also synthesize opines, novel low molecular weight derivatives of amino acids, keto acids or sugars that can serve as a sole source of carbon and/or nitrogen for the inciting Agrobacterium strain. 15,16 Opines are not synthesized by the inciting Agrobacterium strain itself. 16 The mRNA for lysopine dehydrogenase, the enzyme that synthesizes the opine octopine (N2[D-1-carboxyethyl]-L- arginine), is encoded by T-DNA from octopine specific Ti plasmids. 17,18 There are an additional six polyadenylated transcripts found in octopine synthesizing tumors 12 that may encode polypeptides important in the synthesis of other opines, tumor morphology, and growth rate. 19,20 A very low level of nonspecific transcripts of T-DNA has been reported in Agrobacterium. 21

The apparent functioning in higher plant cells of genes that derive from a prokaryote is surprising. One might argue either that T-DNA possesses regulatory sequences that promote transcription in eukaryotes, or that T-DNA transcripts originate in flanking plant DNA and are spliced into the observed mature transcripts.

We report here the nucleotide sequence and transcript map of the T-DNA gene that encodes nopaline synthase, the enzyme that synthesizes the opine nopaline. Our results show that the gene is preceded by T-DNA sequences that have a high degree of homology with regions of eukaryotic genes known to be transcribed by RNA polymerase II. These homologies allow us to draw the conclusion that, in the case of this gene at least, T-DNA contains sequences typical of eukaryotic promotors, and may not rely on a complex read-through mechanism from an adjacent plant promotor for expression. The nopaline synthase gene is unlike many other eukaryotic structural genes in that it lacks intervening sequences.

MATERIALS AND METHODS

Nucleic Acid Sequencing

A 3.4 kb Hind III fragment (Hind III fragment 23) that contains the nopaline synthase gene of pTi T37^{22,23} was subcloned into pBR325^{24,25} from a Charon 4A²⁶ library of pTi T37 constructed by N. Yadav. The Hind III fragment was purified from an agarose gel and ligated to M13 mWB2341²⁷ replicative form DNA which had been cleaved with Hind III and treated with calf intestine alkaline phosphatase. mWB2341 has sequences complementary to the 15-base universal primer followed by a unique Eco RI site, a unique Hind III site, and the lac operator. Recombinant phage were identified from their genome size as determined by analysis of infected bacteria by the toothpick assay.²⁸ Both orientations of the Hind III fragment were identified by annealling small aliquots of culture supernatants in pairs at 68° C for several hours, and electrophoresing the mixture in 0.7% agarose gels.²⁷ The M13 constructs carrying Hind III fragment 23 in each orientation are called mTi23.2 and mTi23.11. Replicative form of the recombinant phage DNA was prepared using the cleared lysate procedure.²⁹

We developed a method that enabled us to obtain systematic sequence data from the 3.4 kb Hind III insert in mWB2341. This method is generally applicable to any insert in the appropriate strains of M13, and is described in detail in the adjacent paper. ²⁷ Briefly, 5 ug of the recombinant M13 replicative form DNA was treated with DNase I in the presence of ethidium

bromide such that each molecule was nicked once randomly. This nick was then widened to a gap by a very limited digestion with Exonuclease III, and the exposed single-stranded DNA was digested with Bal 31 nuclease. The linear DNA motecules were then made flush-ended by treatment with the large fragment 30 of DNA polymerase I. and ligated to a hundred-fold molar excess of Eco RI linkers. After passage over a small column of Biogel Al5 M to remove excess linkers, the DNA was digested with a large excess of Eco RI, phenol extracted, and ligated at a final concentration of approximately 2-5 ug/ml to promote recircularization of DNA molecules. These treatments resulted in the creation of a deletion extending from the Eco RI site in mWB2341 adjacent to the universal primer site to the point of the random DNase nick, with a (linker) Eco RI site at the deletion boundary. Transformation of these deleted circular molecules into competent E.coli allowed selection for phage that had deletions terminating in the Hind III insert DNA, since deletions extending a short distance past the insert DNA rendered the phage non-viable. The size of each deletion was easily estimated by electrophoresing a small sample of lysed, intected cells in agarose gels. 28 In this way asymmetric deletions of a range of sizes were catalogued and sequenced to give overlapping spans of data. Each span of data obtained is indicated schematically in figure 1 and exactly in figure 2.

Three sequencing experiments indicated in figure 2 did not arise from the kilo-sequencing strategy. MTi35 and mTi40 are inserts of Hind III - Sst II fragments in mWB2341 as described. Clone 2-6 is the 920 bp Hpa II fragment inserted into the Acc I site of M13mp7.

Sequence reactions were conducted according to Sanger et al.³² with slight modifications²⁷ and the products were electrophoresed in thin 8% acrylamide/7M urea gels³³ in pH 8.8³⁴ Tris-borate electrophoresis buffer. Radiolabelling and isolation of DNA fragments

For estimating the position of the 5' end of the transcript, a 920 bp Hpa II fragment was purified from the 3.4 kb Hind III fragment 23 cloned in pBR325. Five micrograms of this isolated fragment were digested briefly with 0.5 ug of Exonuclease III at 15°C for 90 seconds to further expose the 5' ends for efficient phosphorylation. The reaction was terminated by phenol extraction and ethanol precipitation and the fragments were dephosphorylated with 10 U of calf intestine alkaline phosphatase at 60°C for 1 hr. The reaction was terminated by phenol extraction and ethanol precipitation, and the product was rephosphorylated with T4 DNA kinase and 6^{-32} P ATP as described. The kinase reaction was terminated by heating to 70°C for 10




Figure 1A. Map of the target DNA region from Hind III fragment 23 of the right border region of T-DNA from pTi-T37. This map is in the standard orientation, opposite to the orientation of the sequence as presented in figure 2. The sequence is incomplete between the right border and the end of the Hind III fragment, but the number of sites encountered so far in that region are indicated after a colon (:). No sites were encountered for AccI, ApoI, BglII, EcoRI, HpaI, KpnI, MluI, NaeI, NarI, PstI, SmaI, SstI, SalI, TthII. XbaI, ShoI, XmmI.

Figure 1B. Spectrum of deletions chosen for sequencing data to cover the right border of T-DNA and the nopaline synthase gene. The arrows represent sequence data; thus the deletion endpoints are at the bases of the arrows. For scale, the positions of the unique BamHl and SstII sites are indicated, with the first base of the leftmost HindIII site as nucleotide number 1.

Three of the sequencing experiments shown are not from the kilo-deletion procedure: mTi35, mTi40, and mTi2-6 (see Methods). The experiments with mTi23.2 deletions are shown in the upper portion of the figure and are, from left to right for the deletion endpoints: mTi23.2.38N (undeleted, actually), mTi23.2.2N, mTi23.2.51N, mTi23.2.68N, mTi23.2.39N, mTi23.2.46N, mTi23.2.8, [mTi2-6], mTi23.2.64N, mTi23.2.77N, mTi23.2.68, [mTi40], mTi23.2.67, mTi23.2.49n, mTi23.2.66n, mTi23.2.67N. The mTi23.11 deletions in the lower portion of the figure are, from right to left: mTi23.11.66 (undeleted, actually), mTi23.11.65, [mTi35], mTi23.11.A1, mTi23.11.73, mTi23.11.A4, mTi23.11.A24, mTi23.11.A32, mTi23.11.A26, mTi23.11.B2, mTi23.11.A20, mTi23.11.B2, mTi23.11.A20, mTi23.11.B2, mTi23.11.A20, mTi23.11.94, mTi23.11.92, mTi23.11.96, mTi23.11.93, mTi23.11.A11. The sequence to the right, outside T-DNA, is under determined at this time.

minutes, and the product was diluted to 250 ul with Sst II salts and digested with Sst II. The two labelled fragments were separated by electrophresis in a 5% acrylamide gel, and the 314 bp fragment was purified by electroelution and DEAE Sephadex column chromatography for use as a hybridization probe.

For mapping the 3' end of the nopaline synthase transcript, the 3.4 kb Hind III fragment 23 cloned in pBR325 was cleaved with Bam HI and briefly digested with Exonuclease III as previously described. The reaction was terminated by phenol extraction and ethanol precipitation, and the exposed 5' end was filled in with 100 uM dGTP, dTTP, dCTP and 2.5 uM 50 mM NaCl, 10 mM tris HCl, pH 7.9, 10 mM MgCl, 10 mM beta-mercaptoethanol, and 2.5 units of Klenow polymerase at 37°C for 30 minutes. This enabled the 3' ends of the DNA fragment to become radiolabelled to a high specific activity, and completely filled in as judged by electrophoresis of the radiolabelled fragment in a denaturing polyacrylamide gel. The end-filling reaction was terminated by heating the reaction to 70°C for 10 minutes, and then diluting it to 250 ul with Hind III salts. The fragments were digested with Hind III, resolved by electrophoresis in 1% agarose gels, and the 1.1 kb Hind III - Bam HI fragment complementary to the 3' end of the nopaline synthase gene was purified by electroelution and DEAE Sephadex chromatography. RNA isolation, hybridization and Sl nuclease digestion

RNA was isolated from freeze-dried BT37 tumor (incited by A. tumefaciens T37 on Nicotians tabacum var. Havana 425 by Dr. A.C. Braun) tissue using the guanidine thiocyanate method. 36 Poly A+ RNA was selected by three passages over oligo-dT cellulose as described. 37 Poly A+ RNA (50 ug) was hybridized with approximately 0.1 ug of denatured end-labelled DNA fragments in 20 ul of 80% formamide, 0.4 M NaCl, 0.05 M PIPES, pH 6.4, 0.001 M EDTA AT 48°C for 8-12 hrs. Nuclease S1 reactions were initiated by rapidly diluting the hybridization mixture into 10 volumes of ice-cold S1 nuclease buffer containing an appropriate amount of S1 nuclease. The reaction was brought to room temperature (approximately 20-22°C) and incubated for 2 hrs, after which it was terminated by phenol extraction and ethanol precipitation. Exonuclease VII reactions were carried out in S1 nuclease buffer with 0.5 U of enzyme at 45°C for two hours, after which the reaction was terminated by phenol extraction and ethanol precipitation.

For mRNA termini mapping experiments, S1 nuclease resistant DNA fragments were electrophoresed in either 5% or 8% polyacrylamide/7M urea sequencing gels. 33 An equal amount of polyadenylated RNA isolated in an identical way from normal, non-tumorous callus of Nicotiana tabacum var. Havana 425 was used

```
~3400
                               2330
                                         2320
                                                   2310
                                                             2300
     AAGCTTCGACAA.....AATATCCGATTATTCTAATAAACGCTCTTTTCTCTTAGGTTTACCCGCCA
    HindIII
                                      ...23.2.67
                  Right border of T-DNA
       nonT-DNA<-->T-DNA
                                         2250
                                                   2240
                                                                       2220
                     2270
                               2260
     ATATATCCTGTCAAACACTGATAGTTTAAACTGAAGGCGGGAAACGACAATCTGATCATGAGCGGAGAAT
23.2.55N<-
   12/14 repeat
                                                             2160
                                                                       2150
           2210
                     2200
                               2190
                                         2180
                                                   2170
     TAAGGGAGTCACGTTATGACCCCCGCCGATGACGCGGGACAAGCCGTTTTACGTTTGGAACTGACAGAAC
                                            ..23.2.68
                                           ..23.2.77N
           2140
                     2130
                                         2110
                                                   2100
                                                             2090
                                                                        2080
                             SstII
     CGCAACGTTGAAGGAGCCACTCAGCCGCGGGTTTCTGGAGTTTAATGAGCTAAGCACATACGTCAGAAAC
                                ..23.2.64N
                                                      23.2.67<-
                        mTi40<- ->mTi35
                               2050
                                         2040
           2070
                     2060
                                                   2030
                                                             2020
     CATTATTGCGCGTTCAAAAGTCGCCTAAGGTCACTATCAGCTAGCAAATATTTCTTGTCAAAAATGCTCC
                                        5' of mRNA
           2000
                     1990
                               1980
                                         1970
                                                   1960
                                                             1950
                                                                       1940
     ACTGACGTTCCATAAATTCCCCTCGGTATCCAATTAGAGTCTCATATTCACTCTCAATCCAAATAATCTG
                                         ..23.2.8
  23.22.68<-
       Nopaline synthase gene
                    1920
                               1910
                                         1900
                                                   1890
                                                             1880
                                                                        1870
     CAATGCCAATTACCTTATCCGCAACTTCTTTACCTATTTCCGCCGCAGATCACCATCCGCTTCCCTTGAC
               23.2.77N<-
                                                  23.2.64N<-
                                                  mTi35..
       MetAlaIleThrLeuSerAlaThrSerLeuProIleSerAlaAlaAspHisHisProLeuProLeuTh
                     1850
                               1840
                                         1830
                                                   1820
                                                             1810
     CGTAGGTGTCCTCGGTTCTGGTCACGCGGGGACTGCATTAGCGGCTTGGTTCGCCTCCCGGCATGTTCCC
                  ->23.11.A1
                                       ->23.11.73
                                                            2-6<-
     {\tt rValGlyValLeuGlySerGlyHisAlaGlyThrAlaLeuAlaAlaTrpPheAlaSerArgHisValPro}
           1790
                     1780
                               1770
                                         1760
                                                   1750
                                                             1740
                                                                        1730
     ACGGCGCTGTGGGCACCAGCAGATCATCCAGGATCGATCTCAGCAATCAAGGCCAATGAAGGAGTTATCA
                ..23.2.46N
     ThrAlaLeuTrpAlaProAlaAspHisProGlySerIleSerAlaIleLysAlaAsnGluGlyValIleT
                    1710
                               1700
                                         1690
                                                   1680
     CCACCGAGGGAATGATTAACGGTCCATTTAGGGTCTCAGCCTGTGATGACCTTTGCCGCAGTTATTCGCTC
            ..23.2.39N
                                        23.2.8<-
    23.11.A1..
    hrThrGluGlyMetIleAsnGlyProPheArgValSerAlaCysAspAspLeuAlaAlaValIleArgSe
          1650
                     1640
                               1630
                                         1620
                                                   1610
                                                             1600
    CAGCCGTGTACTGATTATTGTAACCCGTGCGGACGTTCACGACAGCTTCGTCAACGAACTCGCCAACTTC
                     23.2.46N<-
                                                    23.11.73..
    rSerArgValLeuIleIleValThrArgAlaAspValHisAspSerPheValAsnGluLeuAlaAsnPhe
```

```
1520
                                                                        1550
                                                                                           1540
              1580
                                 1570
                                                    1560
 AACGGCGAACTCGCAACAAAGGATATTGTCGTCGTGTGCGGCCATGGCTTCTCCATCAAGTACGAGAGAC
                                         ->23.11.A24 ->23.11.A32
 AsnGlyGluLeuAlaThrLysAspIleValValValCysGlyHisGlyPheSerIleLysTyrGluArgG
                                                                                                                                   1450
PvuII 1510
                                 1500
                                                    1490
                                                                        1480
                                                                                            1470
                                                                                                               1460
 AGCTGCGATTCAAGCGAATATTCGAGACGGATAATTCGCCCATAACGTCTAAGCTATCGGATCAAAAAAA
                                                                                                            ..23.2.68N
                                                                                          23.11.A4.. 23.2.39N<-
 InLeuArgPheLysArgIlePheGluThrAspAsnSerProIleThrSerLysLeuSerAspGlnLysLy
                                                                                                                                   1380
                                                                                            1400
                                                                                                               1390
              1440
                                 1430
                                                    1420
                                                                        1410
  ATGTAACGTCAACATCAAGGAAATGAAAGCGTCTTTCGGACTGTCATGTTTCCCAATTCATCGCGATGAT
                                                                                                          23.11.A24..
                                                                                                                        ->23.11.82
  sCysAsnValAsnIleLysGluMetLysAlaSerPheGlyLeuSerCysPheProIleHisArgAspAsp
                                 1360
                                                     1350
                                                                        1340
                                                                                            1330
  GCTGGCGTGATTGATCTACCCGAAGATACCAAGAACATCTTTGCCCAGCTATTTTCCGCTAGAATCATCT
                                     ->23.11.A26
                                                                        23.11.A32..
  AlaGlyValIleAspLeuProGluAspThrLysAsnIlePheAlaGlnLeuPheSerAlaArgIleIteC
                                 1290
                                                                                                               1250
                                                                                                                                   1240
              1300
                                                     1280
                                                                        1270
                                                                                            1260
  GCATCCCGCCGTTGCAAGTGCTATTCTTTTCCAACTATATCACTCATGCGGTTCCGGCAGTCATGAACAT
                                                                                                            23.2.68N<-
  ysIleProProLeuGlnValLeuPhePheSerAsnTyrIleThrHisAlaValProAlaValMetAsnIl
                                 1220
                                                                                                                1180
              1230
                                                     1210
                                                                        1200
                                                                                            1190
  CGGAAGACTCCGCGACCCAGCCAATTCTCTTACTAAAAGAGCTGAGAAGTGGCTTCTTGAACTAGACGAG
           23.11.A26..
  eGlyArgLeuArgAspProAlaAsnSerLeuThrLysArgAlaGluLysTrpLeuLeuGluLeuAspGlu
               1160
                                  1150
                                                      1140
                                                                         1130 BamHl
                                                                                                                1110
                                                                                                                                    1100
  CGAACCCCACGAGCCGAGAAGGGCTTTTTCTTTTATGGTGAAGGATCCAACACTTACGTTTGCAACGTCC
                                                                                          23.11.82..
                                          ->23.11.86
                                                                                        ->23,11,95
  ArgThr ProArgAlaGluLysGlyPhePhePheTyrGlyGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValCysAsnValGluGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThrTyrValGlySerAsnThr
               1090
                                  1080
                                                     1070
                                                                         1060
                                                                                            1050
                                                                                                                1040
                                                                                                                                    1030
   AAGAGCAAATAGACCACGAACGCCGGAAGGTTGCCGCAGCGTGTGGATTGCCGTCTCAATTCTCTCTTGCA
   lnGluGlnIleAspHisGluArgArgLysValAlaAlaAlaCysGlyLeuArgLeuAsnSerLeuLeuGl
               1020
                                  1010
                                                     1000
                                                                           990
                                                                                               980
                                                                                                                                     960
   GGAATGCAATGATGAATATGATACTGACTATGAAACTTTGAGGGAATACTGCCTAGCACCGTCACCTCAT
                                                                                                                        ->23.11.A22
  nGluCysAsnAspGluTyrAspThrAspTyrGluThrLeuArgGluTyrCysLeuAlaProSerProHis
                                                       930
                                                                           920
                                                                                               910
   AACGTGCATCATGCATGCCCTGACAACATGGAACATCGCTATTTTTCTGAAGAATTATGCTCGTTGGAGG
                                                      23.2.51n<-
                                              23.11.95..
  AsnValHisHisAlaCysProAspAsnMetGluHisArgTyrPheSerGluGluLeuCysSerLeuGluA
                                    870
                                                       860
                                                                           85Q
                                                                                               840
   ->23.11.A2
   spValAlaAlaIleAlaAlaIleAlaLysIleGluIleProLeuThrHisAlaPheIleAsnIleIleHi
```

```
800
                        790
                                  780
                                           770
TGCGGGGAAAGGCAAGATTAATCCAACTGGCAAATCATCCAGCGTGATTGGTAACTTCAGTTCCAGCGAC
        ->23.11.A20
                                     23.11.48..
  ->23.11.85 23.11.A22..
sAlaGlyLysGlyLysIleAsnProThrGlyLysSerSerSerValIleGlyAsnPheSerSerSerAsp
                                           700
                        720
                                  710
                                                    690
TTGATTCGTTTTGGTGCTACCCACGTTTTCAATAAGGACGAGATGGTGGAGTAAAGAAGGAGGAGTGCGTCGA
                        ..23.2.2n
                                                        23.11.A20..
LeuIleArgPheGlyAlaThrHisValPheAsnLysAspGluMetValGlu.oc
               660
                        650
                                 640
                                                             610
AGCAGATCGTTCAAACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCGATGATT
                     Unused
                                           23.11.A2..
.11.94
                                         23.11.85..
                     poly A site
      600
                         580
                                  570
                                           560
                                                    550
                                                              540
3' end of mRNA
      530
                                  500
                                           490
                                                    480
                                                              470
               520
                        510
GATGGGTTTTTATGATTAGAGTCCCGCAATTATACATTTAATACGCGATAGAAAACAAAATATAGCGCGC
                        440
                                           420
                                  430
->23.11.92
                        23 - 2 - 2n<-
                                           350
                                                    340
                380
                         370
                                  360
TGACGATGAGCA ATCGAGAGGCTGACTAACA AAAGGTATGCCCA AAAACAACCTCTCCCA AACTGTTTCGA
                              23.11.94..
                                                 ->23,11,96
                         300
                                  290
                                           280
                                                              260
      320
                310
ATTGGAAGTTTCTGCTCATGCCGACAGGCATAACTTAGATATTCGCGGGCTATTCCCACTAATTCGTCCT
          23.11.92..
                         230
                                  220
                                           210
                                                     200
                                                              190
                240
GCTGGTTTGCGCCAAGATAAATCAGTGCATCTCCTTACAAGTTCCTCTGTCTTGTGAAATGAACTGCTGA
      ..23.2.38N
      180
                170
                         160
                                  150
                                           140
                                                     130
                                                              120
CTGCCCCCAAGAAAGCCTCCTCATCTCCCAGTTGGCGGCGGCTGATACACCATCGAAAACCCACGTCCG
        ..23.2
                                  ->23.11.A11
                          23,11,96,,->23,11,93
                100
AACACTTGATACATGTGCCTGAGAAATAGGCCTACGTCCAAGAGCCAAGTCCTTTCTGTGCTCGTCGGAAA
                                                         23.11.93..
                                       HindIII
TTCCTCTCTGTCAGACGGTCGTGCGCATGTCTTGCGTTGATGAAGCTT
                                    23.2.38N<-
                                   23.11.A11..
```

as a control in all experiments.

Sizing of nopaline synthage transcripts

Five micrograms of poly A+ RNA isolated from BT37 tumor or normal Havana 425 tissue was glyoxalated and electrophoresed through a 1.8% agarose get, ³⁸ blotted onto activated APT paper, and hybridized with nick-translated ³⁹ Hind III fragment 23 cloned in pBR325. Hybridization and washing conditions were those used by Alwine et al. ⁴⁰

The nopaline synthase transcript was also sized by hybridizing 25 ug of polyadenylated RNA from BT37 tumor to 50 ng of purified, denatured Hind III fragment 23 DNA in 80% formamide, as used for RNA termini mapping experiments. The RNA-DNA hybrids were digested with 81 nuclease and Exonuclease VII and electrophoresed through a 1.8% agarose gel containing 0.03 M NaOH, 0.002 M EDTA, bloted onto activated APT paper, and hybridized to nick-translated Hind III fragment 23 cloned in pBR325.

RESULTS

Nucleotide sequence of the nopaline synthase gene

The kilo-sequencing strategy 27 was used to apply the chain termination method 32 to obtain the nucleotide sequence of the nopaline synthase gene. This strategy is described in detail in the adjacent paper. 27

Fragment Hind III 23 is an all-bacterial DNA fragment which spans the right border region of the T-DNA of pTi T37. Asymmetric deletions were

<u>Figure 2.</u> DNA sequence from HindIII fragment 23 spanning the right border of T-DNA from the nopaline Ti plasmid pTiT37 of <u>Agrobacterium tumefaciens</u>. This presentation is reversed from the standard map orientation, in order to show the non-template (+) strand of the nopaline synthase gene. The sequence is numbered from the HindIII site on the right, which would be on the left in the standard map orientation. The gap in the sequence between nucleotides 3400 and 2330 is from outside T-DNA, and this sequence is under determined at this time.

The data spans for all of the successful sequencing experiments are shown. The start of each data span is the tail of the arrow (->). The end of each data span (the top of the sequencing gel) is indicated with the name of the experiment with two dots (..). With three exceptions, (2-6, mTi35, mTi40) the data was obtained by the kilo-sequencing(24) strategy, so that each experiment represents a deletion available on MI3 transducing phage. Each deletion extends from the tail of the arrow to the end of the HindIII fragment. All strains labelled mTi23.11 carry deletions to the left, with sequencing data toward the right (+ strand sequence on the gel). All strains labelled mTi23.2 have the opposite orientation (deleted toward the right of the arrow, - strand sequence on the gel.)

For example, deletion 23.2.77N has deleted all but 6 codons of the nopaline gene, and retains the promoter region on, therefore, a HindIII-EcoRI fragment. Other labelled features of the sequence are discussed in the text.

generated in the replicative form of M13 phage clones containing Hind III fragment 23 inserted in both orientations at the unique Hind III site of mWB2341. Phage genomes were sized on agarose gels and those that appeared to have deletions differing by 150-200 bp were catalogued and sequenced. In general, this allowed approximately 50 bases of overlap between data from adjacent deletions. The sequence of one strand was confirmed by sequencing appropriate deletions from phage that contained Hind III fragment 23 cloned in the opposite orientation.

The nucleotide sequence from the Hind III site just within T-DNA to a point beyond the right border of T-DNA is shown in Figure 2. The sequence is numbered from 1 to 2400, with nucleotide 1 corresponding to the 5' adenine residue of the Hind III recognition sequence, and nucleotide 2277 corresponding to the last base pair of T-DNA as previously determined. 5,8,9 An open translation reading frame (1239 base pairs, 413 amino acids) extended from nucleotide 1937 to nucleotide 699, an ochre terminator. Although confirming amino acid sequence data are not available, we identify this as the gene for nopaline synthase, since insertion of a 2.3 Md fragment of the P type plasmid R702, encoding streptomycin and sulphonamide resistance, into the unique Bam HI site at nucleotide 1126 is known to abolish nopaline synthesis. 23 Other reading frames extending 1 kb in either direction from the Bam H1 site at nucleotide 1126 were frequently punctuated with terminator codons. The calculated molecular weight of the polypeptide encoded by this open reading frame is 45460 daltons. Kemp et al 41 estimated the molecular weight of nopaline synthase to be 40,000 daltons by electrophoresis of the purified protein in denaturing acrylamide gels. [If their result were taken as extremely accurate, it would indicate either post-translational processing or a translation start at the second AUG, position 1718 (calculated MW = 38188).]

Localization of the 5' end of nonaline synthase mRNA

A 920 bp Hpa II fragment extending from nucleotide 1810 within the open reading frame to a point beyond the sequenced region outside T-DNA was labelled at its 5' extremities with gamma-32P ATP and then cleaved with Sst II to create a fragment of length 314 uniquely labelled at nucleotide 1810. This fragment was hybridized with polyadenylated RNA isolated from BT37 teratoma tissue and then digested with S1 nuclease.

Figure 3 shows an autoradiograph of an 8% sequencing gel of the S1 nuclease-resistant DNA fragments. The autoradiograph reveals a band of radioactive DNA 160 nucleotides long. This indicates that the putative

nopaline synthase mRNA protects a region of DNA extending from the Hpa II site at nucleotide 1810 to approximately nucleotide 1970. A ten-fold increase in S1 nuclease concentration caused only a slight truncation of the protected fragment to one 2 nucleotides smaller.

Reference to an A+G degradation reaction (Maxam and Gilbert, 1980) of the same radiolabelled Hpa II - Sst II fragment run beside the Sl degradation reaction shows the putative 5' end is located opposite the sequence CTCT, which is AGAG of the + strand, at nucleotides 1974 to 1971. These nucleotides are 25 nucleotides downstream from the sequence CATAAA. This bears a close resemblance to the canonical TATAAA consensus sequence that is generally found




Figure 3. Sl nuclease mapping of the 5' terminus of the nopaline synthase transcript. Shown is an autoradiogram of an 8% polyacrylamide sequencing gel used to size the Sl nuclease-resistant DNA fragments. A+G: piperidine formate degradation of the 314 nucleotide Hpa II - Sst II fragment. 100 Sl tumor: 100 U/ml Sl nucleas digestion of tumor polyadenylated RNA hybridised to the 314 nucleotide Hpa II - Sst II fragment. 1000 Sl tumor: Similarly, but with ten times more Sl/ml. 100 Sl normal: 100 U/ml Sl nuclease digestion of normal callus polyadenylated RNA hybridised to the 314 nucleotide Hpa II - Sst II fragment. 0 Sl: A small portion of the intact 314 nucleotide Hpa II - Sst II fragment. MW: 3' end-labelled Hpa II digestion of pBR322 DNA.

25 to 33 nucleotides upstream of RNA polymerase II transcription initiation sites in eukaryotes. 42 The transcription of T-DNA genes is very sensitive to alpha-amanitin, 43 which implicates RNA polymerase II in their transcription. At position 2051-2043 was found the sequence GGTCACTAT, which (along with 14 other places in the 2400 base pairs shown here) has a 7/9 match with the consensus CCAAT box 44 (GGYCAATCT), often found, as here, 70-80 nucleotides upstream from the proposed site of transcription initiation.

Although a definitive identification of the precise 5' terminus of the nopaline synthase mRNA awaits a sequence analysis of the mRNA, our S1 nuclease protection data suggest that nopaline synthase transcription initiation signals are consistent with those of several other eukaryotic structural genes.

Localization of the 3' terminus of nopaline synthase mRNA

A clone of Hind III fragment 23 in pBR325 was cleaved with Bam HI, and labelled at its 3' termini with the Klenow fragment of E. coli DNA polymerase as described in Materials and Methods. The DNA fragments were then cleaved with Hind III and resolved by electrophoresis in 1% agarose. The fragment containing nucleotides 2 to 1126 was isolated by electroelution, chromatography on DEAE-Sephadex, and ethanol precipitation. The radioactive fragment was hybridized with polyadenylated RNA isolated from BT37 teratoma tissue and then digested with S1 nuclease. Figure 4 shows an autoradiograph of a 5% acrylamide sequencing gel of the Sl nuclease-resistant DNA fragments. It reveals an intense band of 605-610 bases, and two fainter bands of approximately 600 to 598 bases. This result suggests that nopaline synthase mRNA terminates at heterogenous sites, with a major site at nucleotides 514-520, and two minor sites at nucleotides 524 and 526. Inspection of the sequence reveals that the mRNA terminates in AT rich sequences, and as a consequence some of the S1-resistant fragments may be caused by "breathing" of the RNA-DNA duplex during Sl nuclease digestion. Although this was minimized by conducting the Sl digestion at 20 C, it is possible that the two minor, shorter, S1 resistant fragments are artefacts.

These putative 3' ends are not closely preceded by a perfect canonical polyadenylation signal 5' AAUAAA, often found 15-20 nucleotides before the point of poly A addition. 45,46 There is however an apparently unused AAUAAA at position 656-651, some 130 nucleotides before the actual 3' end observed here.

Size of the popaline synthase mRNA

The distance between the putative 5' and 3' termini of the nopaline

synthase gene measures approximately 1460 nucleotides. Two methods were used to measure the size of the mature nopaline synthase transcript and confirm this estimate.

Firstly, polyadenylated RNA isolated from BT37 teratoma tissue was denatured with glyoxal and electrophoresed in 1.8% agarose gels, blotted onto activated APT paper, and hybridized with nick-translated Hind III fragment 23. A radioactive band of 1550-1600 nucleotides was revealed (Figure 5A), which is consistent with the length inferred from sequence data plus a 3' polyadenylic acid tract, which appears therefore to be 100-150 bases long.

Secondly, 50 ng of purified Hind III fragment 23 was denatured and hybridized with 25 ug of polyadenylated BT37 teratoma RNA in 80% formamide as




Figure 4. SI nuclease map of the 3' terminus of the nopaline synthase transcript. Shown is an autoradiogram of a 5% sequencing gel used to size SI nuclease-resistant DNA fragments. O SI: Intact 1125 nucleotide Hind III - Bam H1 fragment used in the hybridization experiment. Normal RNA: 1125 nucleotide Hind III - Bam H1 fragment hybridized to normal callus polyadenylated RNA and digested with 100 U/ml SI nuclease. Tumor RNA: 1125 nucleotide Hind III - Bam H1 fragment hybridized to polyadenylated RNA isolated from tumors and digested with 100 U/ml SI nuclease. MW: Two loading amounts of pBR322 DNA digested with Hpa II and 3' end-labelled, and 1 loading of phage lambda DNA digested with Eco RI and Hind III and 3' end-labelled.

described in Materials and Methods, and then digested with either S1 nuclease or Exonuclease VII. The resulting DNA fragments were electrophoresed in an alkaline 1.8% agarose gel together with appropriate molecular weight markers, blotted onto activated APT paper, and hybridized with nick-translated Hind III fragment 23. A radioactive band of 1450-1500 bases was revealed (Figure 5B) when the RNA-DNA duplex was digested with S1 nuclease and with Exonuclease VII. This is consistent with the transcript size of 1460 bases inferred from sequence data, and the observed size on Northern blots of 1550-1600 bases. In addition, the similar size of the Exonuclease VII and S1 nuclease-resistant hybrid molecules shows that RNA protects a continuous length of approximately 1450 nucleotides. This is evidence that the nopaline synthase gene is not




Figure 5. The size of the nopaline synthase transcript.

A) An autoradiogram of a gel of polyadenylated tumor and normal callus RNA blotted onto activated APT paper, and hybridized to nick-translated Hind III fragment 23, is shown. Molecular weight markers (not visible) were glyoxalated plant and E. coli rRNA species, and chimp globin mRNA.

B) An autoradiogram of an alkaline gel of S1 nuclease and Exo VII-resistant DNA fragments blotted onto nitrocellulose and hybridized to nick-translated Hind III fragment 23 is shown. Normal: digestion of normal callus polyadenylated RNA hybridized to purified Hind III fragment 23. Tumor: similarly for tumor polyadenylated RNA. Markers: 3' end-labelled Hind III and Eco RI digestion of phage lambda DNA, and 3' end-labelled Hpa II-digested pBR322 DNA.

interrupted by intervening DNA sequences. 47

DISCUSSION

The data presented show that the gene that encodes nopaline synthase has many similarities to "typical" eukaryotic genes despite its prokaryotic origin. This is not surprising as the gene is expressed in the nucleus of higher plants.

The presence of sequences upstream from the putative 5' end of the nopaline synthase mRNA that have a high degree of homology to known eukaryotic promotor sequences provides evidence that the putative 5' end of the mRNA at nucleotide 1964 is the actual 5' end of the mRNA molecule. Because of this, it is unlikely that plant DNA sequences further upstream from the nopaline synthase gene are involved in the regulation of this gene. The absence of introns in this gene is an unusual feature, as many plant structural genes, like animal genes, contain introns.

The nopaline synthase gene promoter is a constitutive plant promoter, as shown by the presence of nopaline in all tissues of shoots that develop from tumors. 51,52 Our determination of the DNA sequence in this region lays the background for engineering of this promoter to express useful proteins in plant cells. Our deletion 23.11.77N, which arose during the sequencing strategy employed, represents a further step in this engineering, since it has deleted all but six codons of the nopaline synthase gene, leaving the nopal promoter and the right border of T-DNA on a Hind III - Eco RI fragment. Should deletion of the remaining 6 codons of the nopaline gene be desirable, limited exonuclease digestion could start at the Eco RI site. As it stands in M13, the deletion 77N has fused the sixth codon of nopaline synthase to the sixth codon of the alpha complementing region of beta-galactosidase, in the same reading frame.

ACKNOWLEDGEMENTS

The authors wish to thank Elodee Tuley, Don Bennett and Jim Grichnik for their able assistance. This research was supported by the NIH (grant no. GM24956 to W.M.B.), the American Cancer Society (Faculty Research Award to W.M.B. and grant NP194 to M.D.C.), the Department of Energy (contract ACO2-81ER 10889, and Monsanto Corporation (postdoctoral fellowship to M.B.).

^{*}Present address: Plant Breeding Institute, Maris Lane, Trumpington, Cambridge CB2 21Q, UK §To whom reprint requests should be sent

REFERENCES

- Zaenen, I., Van Larebeke, N., Teuchy, H., Van Montagu, M. and Schell, J. (1974) Mol.Biol. 86, 109-127.
- Watson, B., Currier, T.C., Gordon, M.P., Chilton, M.-D. and Nester, E.W. (1975) Bacteriology 123, 255-264.
- Chilton, M.-D., Drummond, M.H., Merlo, D.J., Sciaky, D., Montoya, A., Gordon, M.P. and Nester, E.W. (1977) Cell 11, 263-271.
- 4. Yadav, N.S., Postle, K., Saiki, R.K., Thomashow, M.F. and Chilton, M.-D. (1980) Nature (London) 287, 458-461.
- Zambryski, P., Holsters, M., Kruger, K., Depicker, A., Schell, J., Van Montagu, M. and Goodman, H.M. (1980) Science 209, 1385-1391.
- Willmitzer, L., De Beuckeleer, M., Lemmers, M., Van Montagu, M. and Schell, J. (1980) Nature (London) 287, 359-361.
- Simpson, R., O'Hara, P., Kwok, W., Montoya, A.L., Lichtenstein, C., Gordon, M.P. and Nester, E.W., Cell 29 (1982) 1005-1014.
- Zambryski, P., Depicker, A., Kruger, K., and Goodman, H.M. (1982)
 J.Mol.Appl.Genet. 1, 361-370.
- Yadav, N.S., Vanderleyden, J., Bennett, D.R., Barnes, W.M. and Chilton, M.-D., Proc.Nat.Acad.Sci.USA in press.
- Drummond, M.H., Gordon, M.P., Nester, E.W. and Chilton, M.-D. (1977) Nature (London) 269, 535-536.
- Gelvin, S.B., Thomashow, M.V., McPherson, J.C., Gordon, M.P., and Nester, E.W. (1982) Proc. Natl. Acad. Sci. USA 79, 76-80.
- Willmitzer, L., Simons, G., and Schell, J. (1982) The EMBO Journal 1, 139-146.
- McPherson, J.C., Nester, E.W. and Gordon, M.P. (1980) Proc. Natl. Acad. Sci. USA 77, 2666-2670.
- 14. White, P.R. and Braun, A.C. (1942) Cancer Res. 2, 597-617.
- Petit, A., Delhaye, S., Tempe, J. and Morel, G. (1970) Physiol. Veg. 8, 205-213.
- 16. Petit. A. and Tempe, J. (1978) Molec.Gen.Genet. 167 (167) 147-155.
- 17. Schroder, J. and Schroder, G. (1981) FEBS Letters 129, 166-68.
- 18. Murai, N. and Kemp, J. (1982) Proc. Natl. Acad. Sci. USA 79, 86-90.
- Garfinkel, D.J., Simpson, R.B., Ream, L.W., White, F.F., Gordon, M.P., and Nester, E.W. (1981) Cell 27, 143-153.
- Leemans, J., Deblaere, R., Willmitzer, L., de Greve, H., Hernalsteens, J.P., van Montagu, M. and Schell, J. (1982) The EMBO Journal 1, 147-152.
- 21. Gelvin, S.B., Gordon, M.P., Nester, E.W. and Aronson, A.A. (1981) Plasmid 6, 17-29.
- Hernalsteens, J.P., Van Vliet, F., De Beuckeleer, M., Depicker, A., Engler, G., Lemmers, M., Holsters, M., Van Montagu, M. and Schell, J. (1980) Nature (London) 287, 654-656.
- Leemans, J., Shaw, C., Deblaere, R., De Greve, H., Hernalsteens, J.P., Maes, M., Van Montagu, M. and Schell, J. (1981) J. Mol. Appl. Genet. 1, 149-164.
- 24. Bolivar, F. (1978) Gene 4, 121-136.
- 25. Prentki, P., Karch, F., Iida, S. and Meyer, J. (1981) Gene 14, 289-299.
- Williams, B.C. and Blattner, F.R. (1980) in Genetic Engineering (Setlow, J.K. and Hollaender, A., eds.) vol 2, 201-283.
- 27. Barnes, W.M. and Bevan, M. (1982) Nucleic Acid Res.
- 28. Barnes, W.M. (1977) Science 195, 393-394.
- Blair, D.G., Sherratt, D.J., Clewell, D.B. and Helinski, D.R. (1972)
 Proc. Natl. Acad. Sci. USA 69, 2518-2522.
- Klenow, H., Overgaard-Hansen, K. and Patkar, S.A. (1971) Eur. J. Biochem. 22, 371-381.
- Messing, J., Crea, R. and Seeburg, P.H. (1981) Nucleic Acids Res. 9, 309-323.

- Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. Acad. Sci. USA 74, 5463-5467.
- 33. Sanger, F. and Coulson, A.R. (1978) FEBS Lett. 87, 107-110.
- 34. Anderson, S.(1981) Nucleic Acids Res. 9, 3015-3027.
- 35. Maxam, A.M. and Gilbert, W. (1980) in Methods in Enzymology (Gross, L. and Moldaye, K. eds.) vol 65, 499-560.
- Chirgwin, J.M., Przybyla, A.E., Macdonald, R.J., and Rutter, W.J. (1979) Biochemistry 18, 5294-5299.
- 37. Bantle, J.A., Holm, I.H. and Hahn, W.E. (1978) Anal. Biochemistry 72, 413-427.
- 38. McMaster, G.F. and Carmichael, G.G. (1977) Proc. Natl. Acad. Sci. USA 74, 4835-4838.
- 39. Maniatis, T., Jeffrey, A., and Kleid, D.G. (1975) Proc. Natl. Acad. Sci. USA 72. 1184-1188.
- Alwine, J.C., Kemp, D.J., Parker, B.A., Reiser, J., Renart, J., Stark, G.R. and Wahl, G.M. (1979) Methods in Enzymology (ed. by R. Wu) vol 68, 220-242.
- 41. Kemp, J.D., Sutton, D.W. and Hack, E. (1979) Biochemistry 18, 3755-3760.
- 42. Breathnach, R. and Chambon, P. (1981) Ann. Rev. Biochemistry 50, 349-383.
- Efstradiatis, A., Posakony, J.W., Maniatis, T., Lawn, R.M., O'Connell, C., Spritz, R.A., DeRiel, J.K., Forget, B.G., Weissman, S.M., Slightom, J.L., Blechl, A.E., Smithies, O., Baralle, F.E., Shoulders, C.C., and Proudfoot, J.J. (1980) Cell 21, 653-668.
- 44. Willmitzer, L., Schmalenbach, W. and Schell, J. (1981) Nucleic Acid Res. 9, 4801-4812.
- 45. Proudfoot, N.J. and Brownlee, G.G. (1976) Nature 263, 211-214.
- 46. Benoist, R., O'Hare, K., Breathnach, R. and Chambon, P. (1980) Nucleic Acid Res 8, 127-142.
- 47. Berk, A.J. and Sharp, P.A. (1977) Cell 12, 721-732.
- 48. Shah, D.M., Hightower, R.C. and Meagher, R.B. (1982) Proc.Natl.Acad.Sci. USA 79, 1022-1026.
- 49. Sun, S.M., Slightom, J.L., and Hall, T.C. (1981) Nature 289 37-41.
- 50. Wiborg, O., Hyldig-Nielsen, J.J., Jensen, E.O., Paludan, K. and Marcker, K.A. (1982) Nucleic Acids Res 10, 3487-3494.
- 51. Wood, H.H., Binns, A.N. and Broun, A.C. (1978) Differentiation 11, 175-180.
- 52. Wullems, G.J., Molendijk, L., Ooms, G. and Schilpercort, R.A. (1981) Cell 24, 719-727.